

Hajnalka Andrikovics

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6400226/publications.pdf>

Version: 2024-02-01

8
papers

223
citations

1684188

5
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

447
citing authors

#	ARTICLE	IF	CITATIONS
1	Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia. PLoS ONE, 2021, 16, e0253386.	2.5	5
2	Investigation of TGFBI $\hat{\sim}$ 1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 215-223.	2.4	1
3	The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma. Leukemia and Lymphoma, 2018, 59, 710-716.	1.3	1
4	Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common <i>TERT</i> Polymorphism rs2736100. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 98-104.	2.5	21
5	Molecular diagnostics of myeloproliferative neoplasms. European Journal of Haematology, 2015, 95, 270-279.	2.2	67
6	Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica, 2014, 99, 1184-1190.	3.5	83
7	Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 1028-1035.	1.3	30
8	<i>HFE</i> C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 929-934.	2.5	11